Rick Strassman (b. 1952)
American psychiatrist and clinical researcher, and the man who — quietly, at a university hospital in Albuquerque in the early 1990s — reopened the door to legal human psychedelic research in the United States after it had been sealed shut for twenty years. Nearly every clinical psilocybin, MDMA, or DMT trial running today traces its lineage back through the study he ran.
Born February 8, 1952, in Los Angeles, Strassman studied zoology at Pomona College before earning a B.S. in biological sciences with honors at Stanford (1973), then an M.D. with a specialization in psychiatry at Albert Einstein College of Medicine. After a psychiatry residency at UC Davis and a clinical psychopharmacology fellowship at UC San Diego, he joined the University of New Mexico School of Medicine in 1984, where his research initially centered on the pineal gland and melatonin — work significant enough that his group documented the first known role of melatonin in humans. Finding melatonin’s own psychoactive effects too mild to be scientifically interesting, he turned his attention to a far more potent molecule his earlier research had already led him toward: dimethyltryptamine, or DMT.
The DMT studies
From 1990 to 1995, Strassman ran a government-funded clinical study administering DMT — roughly 400 doses across nearly 60 volunteers — under rigorously controlled hospital conditions, becoming the first researcher in two decades to legally give a classical psychedelic to human subjects in the United States. The study characterized DMT’s dose-response profile and produced the Hallucinogen Rating Scale, a measurement tool that went on to be used in dozens of subsequent studies and remains a standard instrument in psychedelic research today. One especially striking finding: unlike other classical psychedelics, DMT showed no tolerance buildup even with repeated, closely spaced doses.
What made the study famous outside pharmacology circles, though, was what his volunteers reported. Strassman documented experiences carrying many hallmarks of religious experience — visions, voices, disembodied consciousness, overwhelming emotional and existential significance — and, notably, more than half of his volunteers described encountering what felt like nonhuman, conscious beings during the experience. That finding, and Strassman’s own hypothesis that the pineal gland might produce DMT naturally under extreme conditions like birth, death, or dreaming, gave rise to the phrase that would follow him ever after: DMT as “the spirit molecule.”
From clinical data to spiritual inquiry
Strassman published the results as DMT: The Spirit Molecule (2001), a book unusual for pairing hard clinical data with genuine theological and philosophical inquiry into what the experiences meant. A committed Zen practitioner for twenty years by that point, he found that the “more real than real” quality his volunteers described didn’t sit comfortably within a Buddhist framework that treats such visions as mind-generated projections — a mismatch that pushed him toward Hebrew biblical prophecy as, in his view, a better available model for what his subjects had gone through, developed further in DMT and the Soul of Prophecy (2014). The book became a documentary of the same name in 2010, carrying his research to an audience far larger than academic psychopharmacology usually reaches.
His later books have ranged from Inner Paths to Outer Space (2008), on DMT, psychedelics, and the possibility of alien contact experiences, to the more practical The Psychedelic Handbook (2022) and his 2024 memoir My Altered States. Across more than forty peer-reviewed papers and a body of popular writing, Strassman has kept returning to the same central question his own research left him with: not just what these molecules do to the brain, but what to make of the fact that so many people, independently, come back from the same molecule describing something that feels like contact.
Sources: